The Prognostic Value of Angiogenic Markers in Twin Pregnancies to Predict Delivery Due to Maternal Complications of Preeclampsia.
Abruptio Placentae
/ etiology
Adult
Antihypertensive Agents
/ therapeutic use
Area Under Curve
Biomarkers
/ blood
Databases, Factual
Delivery, Obstetric
/ statistics & numerical data
Dyspnea
/ etiology
Female
Gestational Age
HELLP Syndrome
/ etiology
Humans
Infant, Newborn
Membrane Proteins
/ blood
Neovascularization, Physiologic
Pre-Eclampsia
/ blood
Pregnancy
Pregnancy Complications
/ blood
Pregnancy Outcome
Pregnancy, Twin
/ blood
Prognosis
Retrospective Studies
Thrombocytopenia
/ etiology
Vascular Endothelial Growth Factor Receptor-1
/ blood
angiogenic markers
hypertension
suspected preeclampsia
twin pregnancy
Journal
Hypertension (Dallas, Tex. : 1979)
ISSN: 1524-4563
Titre abrégé: Hypertension
Pays: United States
ID NLM: 7906255
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
pubmed:
27
5
2020
medline:
14
4
2021
entrez:
27
5
2020
Statut:
ppublish
Résumé
The sFlt-1 (soluble fms-like tyrosine kinase-1), PlGF (placental growth factor), and their ratio are useful for predicting delivery because of preeclampsia in singleton pregnancies. Evidence on the utility of sFlt-1/PlGF ratio in twin pregnancies is lacking. We aimed to evaluate the predictive value of sFlt-1/PlGF ratio for delivery because of preeclampsia in twins. A retrospective data analysis of 164 twin pregnancies with suspected preeclampsia was performed. The sFlt-1/PlGF ratio, which was known to clinicians, was significantly higher in women who delivered within 1 and 2 weeks compared with those who did not (median: 98.9 and 84.2 versus 23.5 pg/mL, respectively;
Identifiants
pubmed: 32450740
doi: 10.1161/HYPERTENSIONAHA.120.14957
doi:
Substances chimiques
Antihypertensive Agents
0
Biomarkers
0
Membrane Proteins
0
PIGF protein, human
0
FLT1 protein, human
EC 2.7.10.1
Vascular Endothelial Growth Factor Receptor-1
EC 2.7.10.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM